According to filings with the U.S. Securities and Exchange Commission, Allevion Therapeutics is raising up to $1,475,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Shawn Moaddeb played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Allevion Therapeutics
Putting quality of life back within reach. Allevion Therapeutics was incorporated in 2017 in Delaware and filed multiple patent applications covering broad method and techniques for Class II devices. We’re developing a novel smart wrist wearable-tech device that reduces hand tremor, specifically Essential Tremor (ET). Technology allows patients to regain confidence and significantly improves their quality of life. This breakthrough energy system has the potential to address ET and other movement related disorders such as Parkinson’s disease (PD) and Dystonia.

To learn more about Allevion Therapeutics, visit http://www.alleviontx.com/

Contact:
Shawn Moaddeb, Chief Executive Officer
949-615-7488
https://www.linkedin.com/in/shawn-moaddeb-50731818/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.